Mary Caffrey

Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.

Articles highlighting links between COVID-19 and cancer were among the most-read in Evidence-Based Oncology™ in 2023.

An August approval of luspatercept, sold as Reblozyl, which promises to alleviate transfusion burdens for patients with lower-risk MDS, was among the news items that drew readers’ attention.

Regeneron officials say they are on track to file for FDA approval for the bispecific antibody by the end of 2023.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).

The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California.

Robert Rifkin, MD, medical oncologist and hematologist at Rocky Mountain Cancer Centers, shares insight into how the phase 2 Optec study of teclistamab administration in the outpatient setting could help achieve important health equity and quality goals.

In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.

In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center, presented phase 2 results for 25 patients with TP53 mutations.

Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).

Minimal residual disease (MRD) is not accepted by regulators as a surrogate end point, but a commenter at the American Society of Hematology plenary session said one is needed.

Preliminary results showed a small group of patients with CLL had 100% progression-free survival at 9.7 months when taking an investigational BCL2 inhibitor, sonrotoclax, with zanubrutinib.

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (R/R CLL) at 39 months of follow-up.

Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation Bruton tyrosine kinase inhibitor.

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, previewed her presentation of extended follow-up data from the phase 3 ALPINE trial and other studies of interest to CLL specialists at the 2023 American Society of Hematology (ASH) Annual Meeting.

The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.

The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.

The therapy is already approved for certain patients with relapsed/refractory mantle cell lymphoma.

Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.

Desmoid tumors are noncancerous growths that appear in connective tissue, most often on the arms, legs, and abdomen. Aggressive tumors must be treated with surgery, radiation, or chemotherapy to keep them from growing into nearby organs, which can make them life threatening. They can cause pain and disfigurement, and they can reduce functioning and quality of life.

An online survey of patients from multiple countries has shed light on their challenges in getting proper care for ovarian cancer.

Given the likelihood of MDS to progress to acute myeloid leukemia (AML), the authors state, “There are certain settings where ‘AML-like’ therapies are appropriate in MDS, particularly given our evolving understanding of the overlapping biology of these malignancies.”

Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.

Coverage from the Institute for Value-Based Medicine session with Florida Cancer Specialists & Research Institute.

The discussion, "Understanding Biomarkers and the Role They Play in Oncology," came during the Community Oncology Alliance Payer Exchange Summit, held October 23-24 in Reston, Virginia.